Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reticulocyte Peak in Mircera-Treated Hemodialysis Patients
NCT02832323Terminated
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jun 2016
- Primary completion
- Jun 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Open-label, single-arm trial of Epoetin alfa RB in anemia of chronic kidney disease (CKD-A), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Reticulocyte peak at Day 9. Started Jun 2016; status: terminated.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02832323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832323.